Polymer conjugate bonded to tertiary amine compound or imine compound and production method therefor

Patent metadata

Field	Value
Publication number	US-2022257781-A1
Application number	US-201917274073-A
Country	US
Kind code	A1
Filing date	Sep 5, 2019
Priority date	Sep 6, 2018
Publication date	Aug 18, 2022
Grant date	—

Abstract

Provided is a compound as a compound obtained by conjugating a tertiary amine compound or an imine compound, which is useful as a drug, with a polymer, in which a structure D + forming a quaternary ammonium salt or an iminium salt from D, a tertiary amine compound or an imine compound and a polymer residue Poly having a carboxy group are bonded to each other via a structure —C(R 1 )(R 2 )OC(═O)YANHC(═O)—.

First claim

1 . A compound represented by Formula (I) or a pharmaceutically acceptable salt thereof;

[in Formula (I), D + is a structure forming a quaternary ammonium salt or an iminium salt from a tertiary amine compound or an imine compound D; a nitrogen atom of D + forming the quaternary ammonium salt or the iminium salt and a carbon atom to which R 1 and R 2 bond are bonded to each other; Y is O or NR 3 ; R 1 , R 2 , and R 3 are each independently a hydrogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted cycloalkenyl group, a substituted or unsubstituted alkynyl group, a substituted or unsubstituted aromatic group, or a substituted or unsubstituted heterocyclic group; A is a substituted or unsubstituted bivalent hydrocarbon group, may contain one or more heteroatoms at a position except for both ends which are bonded to —Y— or —NH—, and the heteroatoms are each independently selected from the group consisting of —O—, —NH— which may have a substituent, and —S—; any two or three groups of R 1 , R 2 , R 3 , and A may combine together to form a ring; and Poly is a polymer residue and —C(═O)— adjacent to Poly is derived from a carboxy group of the polymer].

2 . The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein the Formula (I) is represented by the following Formula (II);

in Formula (II), D + , R 1 , R 2 , Y and Poly are as defined in claim 1 ; R 4 , R 5 , R 6 , and R 7 are each independently a hydrogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted cycloalkenyl group, a substituted or unsubstituted alkynyl group, a substituted or unsubstituted aromatic group, or a substituted or unsubstituted heterocyclic group; any two or three groups of R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , and R 7 may combine together to form a ring; 1 and n are each independently 0, 1, or 2; and m is 0 or 1.

3 . The compound according to claim 2 or a pharmaceutically acceptable salt thereof, wherein in Formula (I) or (II); R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , and R 7 are each independently a hydrogen atom; a substituted or unsubstituted linear or branched chain alkyl group having carbon number of 1 to 6; a substituted or unsubstituted cycloalkyl group having carbon number of 3 to 8; a substituted or unsubstituted linear or branched alkenyl group having carbon number of 2 to 6; a substituted or unsubstituted cycloalkenyl group having carbon number of 3 to 8; a substituted or unsubstituted linear or branched alkynyl group having carbon number of 2 to 6; a substituted or unsubstituted monocyclic or polycyclic aromatic group having carbon number of 6 to 14; or a substituted or unsubstituted 3- to 8-membered heterocyclic group containing at least one of a nitrogen atom, an oxygen atom, or a sulfur atom as a ring-constituting atom.

4 . The compound according to claim 2 or a pharmaceutically acceptable salt thereof, wherein in Formula (I) or (II), a substituent of alkyl group, a substituent of cycloalkyl group, a substituent of alkenyl group, a substituent of cycloalkenyl group, a substituent of alkynyl group, a substituent of aromatic group, and a substituent of heterocyclic group in the groups represented by R 1 , R 2 , R 3 , R 4 , R 5 , and R 7 are groups selected from a hydroxyl group, an alkyl group, a cycloalkyl group, an alkenyl group, a cycloalkenyl group, an alkynyl group, a halogen atom, an aromatic group, a heterocyclic group, an alkoxy group, a guanidino group, an alkylthio group, an alkoxycarbonyl group, an aryloxy group, an arylthio group, an acyl group, a substituted sulfonyl group, a heterocyclyloxy group, a heterocyclylthio group, an amide group, a ureido group, a carboxy group, a carbamoyl group, an oxo group, a thioxo group, a sulfamoyl group, a sulfo group, a cyano group, a nitro group, an acyloxy group, an azido group, a sulfonamide group, a mercapto group, an alkoxycarbonyl amino group, an aminocarbonyloxy group, a substituted sulfinyl group, a sulfamide group, an aminosulfonyloxy group, an alkoxysulfonyl amino group, a substituted sulfonyloxy group, an alkoxycarbonyl group, an alkoxycarbonyloxy group, an alkoxysulfonyl group, an imino group which may be substituted, an azo group which may be substituted, an Rx(Ry)N group, and an Rx(Ry)(Rz)N + group, Rx, Ry, and Rz are each independently selected from the group consisting of a hydrogen atom, an alkyl group, a cycloalkyl group, an alkenyl group, a cycloalkenyl group, an alkynyl group, an aromatic hydrocarbon group, and a heterocyclic group, and at this time, two or more of Rx, Ry, and Rz may combine together to form a saturated or unsaturated hetero ring.

5 . The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein in Formula (I) or (II), Poly is a water-soluble polymer residue.

6 . The compound according to claim 1 , wherein in Formula (I) or (II), Poly is a polysaccharide residue.

7 . The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein in Formula (I) or (II), Poly is a glycosaminoglycan residue.

8 . The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein in Formula (I) or (II), Poly is a residue of chondroitin, chondroitin sulfate or hyaluronic acid.

9 . The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein a counter anion of D + is an inorganic acid anion or an organic acid anion.

10 . The compound according to claim 1 represented by the following Formula (XX) or a pharmaceutically acceptable salt thereof;

[in Formula (XX), D + , R 1 , R 2 , Y, and A are as defined in claim 1 , and
a moiety represented by

is a polymer excluding a group derived from a carboxy group and a carboxy group; q is the number of compounds condensed with the polymer; and r is the number of carboxy groups].

11 . The compound according to claim 10 or a pharmaceutically acceptable salt thereof, wherein the compound represented by the above Formula (XX) is a compound represented by the following Formula (XXX):

[in Formula (XXX), D + , R 1 , and R 2 are as defined in claim 1 ; R 4 , R 5 , R 6 , and R 7 are as defined in claim 2 ; and q and r are as defined in claim 10 , and
a moiety represented by

is a polymer excluding a group derived from a carboxy group and a carboxy group].

12 . A method for producing a compound represented by the following Formula (I) or a pharmaceutically acceptable salt thereof, the method comprising a step of condensing a compound represented by the following Formula (III) and a polymer having a carboxy group represented by the following Formula (IV):

[in Formulae (I), (III), and (IV), D + , Y, A, R 1 , R 2 , and Poly are as defined in cla

Assignees

• Seikagaku Kogyo Co Ltd

Inventors

• Kobayashi Nobuo
• NAMATSU Kenichi

Classifications

• A61K47/61 Primary

  the organic macromolecular compound being a polysaccharide or a derivative thereof · CPC title

• A61K47/58

  obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin · CPC title

• A61K47/645

  Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT · CPC title

• C08G69/48

  Polymers modified by chemical after-treatment · CPC title

• C08B11/15

  with carbamoyl groups {, i.e. -CO-NH2} · CPC title